D'Haens G, Higgins PDR, Peyrin-Biroulet L, Sands BE, et al. Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT Trials. Inflamm Bowel Dis 2024 Jan 25:izae004. doi: 10.1093.
PMID: 38271613